Johnson & Johnson's COVID-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday.It's a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give pause to people uncertain about which vaccine to get or when they can get one.
"And we are right now completely protective, it would appear 100% protective, against disease that actually does make you go to the hospital, we're 100% protective against death."Mammen said the company was working to file for emergency use authorization from the US Food and Drug Administration"inside of a week." It will be the third company to seek EUA from the FDA for a coronavirus vaccine.
Offit has been vaccinated, but said if he had not, he would first search out a Pfizer or Moderna vaccine, and then if he couldn't find one in reasonable period of time, he would take a Johnson & Johnson vaccine if it was available.Offit said getting one brand of vaccine and later on getting a different vaccine should not pose safety issues.
Plus no cases of severe allergic reaction called anaphylaxis were seen in any of the volunteers, the company said. Mammen said the Janssen vaccine was tested later, after new variants of coronavirus were already circulating. One in particular, called B.1.135, was dominant in South Africa when the vaccine was tested there. This variant has mutations that might be expected to weaken the vaccine's effects somewhat.
CNN nahiya na yung 99% ng johnson hahaha